Established in 2011 by Punit Dhillon, OncoSec Medical Inc. is a San Diego-based biotechnology company pioneering new technologies to stimulate the body’s immune system to target and attack cancer. Through its proprietary technology, OncoSec aims to deliver safer and more effective cancer treatments that can provide long-term benefits for patients.
To date, study results laid the groundwork for OncoSec’s expansion into new DNA-encoded therapeutic candidates and tumor indications. Data also indicates this platform shows clinical activity as a monotherapy and promise as a combination approach.
BusinessInterviews.com: Can you share how your investigational platform, ImmunoPulse™, works? Is there potential for this platform to work outside the field of oncology?